Document is current
Any future updates will be listed below
-
Authors
Ramos-Ramírez, Maritza https://orcid.org/0000-0002-1787-0665
Caballe-Pérez, Enrique https://orcid.org/0000-0001-7703-6675
Lucio-Lozada, José https://orcid.org/0000-0002-6881-4794
Romero-Nuñez, Eunice https://orcid.org/0000-0003-4359-4243
Castillo-Ruiz, Cesar https://orcid.org/0009-0009-8576-9241
Dorantes-Sánchez, Lorena
Flores-Estrada, Diana https://orcid.org/0000-0002-9168-238X
Recondo, Gonzalo https://orcid.org/0000-0002-0127-1019
Barrios-Bernal, Pedro https://orcid.org/0000-0002-5681-5204
Cabrera-Miranda, Luis https://orcid.org/0000-0002-0757-9436
Bravo-Dominguez, Heyman https://orcid.org/0009-0008-3620-1417
Hernández-Pedro, Norma https://orcid.org/0000-0003-1630-8440
Arrieta, Oscar https://orcid.org/0000-0002-1164-3779
- License Information
-
More Information
Article History
Received: 15 May 2024
Accepted: 16 January 2025
First Online: 7 February 2025
Declarations
:
: Oscar Arrieta reports receiving personal fees from Pfizer, Lilly, Merck, and Bristol-Myers Squibb and grants, as well as personal fees from AstraZeneca, Boehringer Ingelheim, and Roche, but none of these are related to this manuscript. The rest of authors declare no affiliations with, or involvement in, any organization any financial interest in the subject matter or materials discussed in this manuscript.
